National Pharmaceutical Industry as a Global Health Power: Minister

Jakarta (ANTARA) – Strengthening the pharmaceutical industry at the national level is the basis for a better global health architecture, Indonesian Health Minister Budi Gunadi Sadikin has said.

“Indonesia’s efforts at the G20 are aimed at building a more resilient Indonesian health security system, including increasing national capacity to produce various vaccines, drugs and diagnostic tools,” Sadikin noted in a written statement received here on Saturday. .

The Minister stressed that efforts to strengthen the global health architecture also include the use of collaborative networks for the manufacture of collaborations and research centers for the development of vaccines, drugs and diagnostic tools. .

Sadikin made the remarks at the World Economic Forum (WEF) meeting for the Distributed Vaccine Manufacturing Collaborative in New York, USA on Wednesday, September 21.

The meeting brought together representatives of WEF members and private industry parties, including the global vaccine industry, namely the World Trade Organization (WTO) and the Joint United Nations Program on HIV and AIDS (UNAIDS).

Sadikin noted that strengthening the health industry and using collaborative networks for manufacturing was one of the achievements of Indonesia’s G20 Presidency in the health sector.

The third meeting of the G20 Health Working Group (HWG) resulted in an agreement to strengthen regulations to support the development of global manufacturing hubs, he noted.

The G20 is a forum for multilateral cooperation made up of 19 major countries and the European Union (EU). The G20 represents more than 60% of the world’s population, 75% of world trade and 80% of world gross domestic product (GDP).

G20 members include South Africa, United States, Saudi Arabia, Argentina, Australia, Brazil, India, Indonesia, United Kingdom, Italy, Japan, Germany, Canada, Mexico, South Korea, Russia, France, China, Turkey and the European Union.

According to Sadikin, global research and manufacturing regulations are one of the important aspects that must be achieved to prepare all countries to face the upcoming pandemics.

G20 member countries are encouraged to publish the rules of international organizations to improve research and manufacturing capabilities.

Several potential collaborations that were identified at the G20 meeting include global biomanufacturing training centers, collaborative research efforts, data sharing mechanisms, public-private partnerships and research and manufacturing ecosystems, a Sadikin points out.

This is also in line with the third pillar of health transformation regarding health resilience system transformation.

The minister said these pillars plan future strategies regarding the certainty and availability of vaccines, diagnostics and treatments that can be produced nationally.

The strategy is implemented by developing research centers and using cooperation with countries in the South, so that at least 50 targets can be produced at the national level from upstream to downstream, he said. concluded.

Related news: The pharmaceutical industry must use research for business development
Related news: Pharmaceutical SOE, merged hospital holdings: Bio Farma
Related News: Ministry provides 10 drug molecules to boost domestic production